Antibody technology has advanced a long way since the early days of Kohler and Milstein's antibody-secreting murine hybridomas; and although Kohler and Milstein's invention was not patented, patent protection for the new generation of murine, chimeric, humanized and human antibody-based drugs is essential to safeguard their future development.